Marijuana Flower Extracts Show Antidiabetic Potential, Cannabinoids Bind Key Diabetes Targets, Finds Study
- Marijuana flower extracts inhibited enzymes linked to blood sugar regulation, enhanced glucose uptake, and contained cannabinoids interacting with key type 2 diabetes therapeutic targets.
- Researchers from the University of the Free State used three extracts (hexane, dichloromethane, methanol) analyzed via GC-MS, identifying cannabinoids like THC, CBD, CBG, CBN, THCV, CBDV, and beta-caryophyllene.
- The methanol extract strongly inhibited α-glucosidase, outperforming the diabetes drug acarbose, while the hexane extract best inhibited α-amylase and increased glucose uptake by 54% in yeast cells.
- Computational modeling showed several cannabinoids, including delta-9 THC and cannabivarin, had strong predicted binding to diabetes-related proteins, though findings are preliminary and require further biochemical and clinical research.
A new laboratory and computational study finds that marijuana flower extracts inhibited enzymes involved in blood sugar regulation, increased glucose uptake and contained several cannabinoids that interacted strongly with major therapeutic targets for type 2 diabetes.
The study, published in Chemistry & Biodiversity, examined Cannabis sativa inflorescences using a combination of in vitro testing and molecular modeling. Researchers were affiliated primarily with the University of the Free State in South Africa.
Researchers prepared three extracts using hexane, dichloromethane and methanol, then analyzed their chemical profiles using gas chromatography-mass spectrometry (GC-MS). The extracts contained numerous cannabinoids and terpenes, including THC, cannabidiol (CBD), cannabigerol (CBG), cannabinol (CBN), tetrahydrocannabivarin (THCV), cannabivarin (CBDV) and beta-caryophyllene.
The extracts were tested against α-amylase and α-glucosidase, enzymes that break carbohydrates into sugars and are established targets of diabetes medications. Researchers also examined glucose uptake, antioxidant activity and nitric oxide inhibition.
The methanol extract produced the strongest α-glucosidase inhibition, with an IC50 of 11.21 micrograms per milliliter, compared with 22.07 micrograms per milliliter for the diabetes drug acarbose. At the highest concentration tested, the methanol extract inhibited α-glucosidase by 96.44%.
For α-amylase, the hexane extract performed best among the marijuana extracts, although it was substantially less potent than acarbose. The hexane extract also produced the strongest glucose-uptake response, increasing glucose uptake in yeast cells by 54% at the highest concentration tested.
Researchers then computationally docked 36 marijuana-derived compounds against five diabetes-related protein targets: α-amylase, α-glucosidase, dipeptidyl peptidase-4 (DPP-4), sodium-glucose cotransporter-2 (SGLT-2) and protein tyrosine phosphatase 1B (PTP1B).
Several cannabinoids showed particularly strong predicted interactions. Delta-9 THC matched the binding score of sitagliptin against DPP-4, while 8-hydroxy-delta-9-THC showed strong binding to SGLT-2. Cannabivarin produced the strongest predicted affinity for PTP1B among the marijuana compounds evaluated.
The researchers stressed that the findings are preliminary. The experiments were conducted in laboratory systems rather than humans or animals, while the molecular docking results predict potential interactions rather than demonstrating therapeutic effects. The chemical analysis was also qualitative, meaning researchers did not determine the concentrations of individual compounds in the extracts. Nevertheless, the authors concluded that marijuana inflorescences contain compounds with “potential antidiabetic activities,” identifying delta-9 THC, 8-hydroxy-delta-9-THC, cannabivarin and THC-7-oic acid as candidates deserving additional biochemical, animal and eventually clinical investigation.
The findings were published September 20 in the Journal of Pain Management.